暂无数据
产品名称
起订量
单价(含增值税)
库存(PCS)
起订数量
-
Recombinant Human Neprilysin/CD1048T/96T￥ 0.001
-
Recombinant Human Neprilysin/CD10GV-P01819-10ug￥ 1800.001
-
Recombinant Human Neprilysin/CD10GV-P01819-50ug￥ 4720.001
-
Recombinant Human Neprilysin/CD10GV-P01819-500ug￥ 14640.001
-
Recombinant Human Neprilysin/CD10GV-P01819-1mg￥ 20400.001
产品简介
| Known as | Neprilysin; Atriopeptidase; Common acute lymphocytic leukemia antigen; CALLA; Enkephalinase; Neutral endopeptidase 24.11; NEP; Neutral endopeptidase; Skin fibroblast elastase; SFE; CD10; MME; EPN |
| Derived from | Human Cells |
| Purity | Greater than 95% as determined by reducing SDS-PAGE. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.4. |
| Storage | Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening.Please minimize freeze-thaw cycles. |
| Endotoxin | Less than 0.1 ng/ug (1 EU/ug) as determined by LAL test. |
| Background | Neprilysin/CD10(NEP) is a zinc metallopeptidase expressed at the cell surface of a variety of cells. The functions is both as an endopeptidase with a thermolysin-like specificity and as a dipeptidyl-carboxypeptidase. NEP has been shown to be involved in the degradation of enkephalins in the mammalian brain and the inactivation of circulating atrial natriuretic peptide. NEP has also been identified as the common acute lymphocytic leukemia antigen (CALLA), and is expressed on the surface of lymphocytes in some disease states. These and other observations have resulted in considerable interest in NEP as a target for analgesics and antihypertensive drugs. NEP is also a major degrading enzyme of amyloid β peptide (Aβ) in the brain, indicating that down-regulation of NEP activity, which could be caused by aging, can contribute to the development of Alzheimer’s disease by promoting Aβ accumulation. |
| 规格 | 10ug50ug500ug1mg |
注意：
1.本产品仅供科研使用。请勿用于医药、临床诊断或治疗，食品及化妆品等用途。请勿存放于普通住宅区。
2.为了您的安全和健康，请穿好实验服并佩戴一次性手套和口罩操作。
暂无数据
我要询价
*联系方式：
(可以是QQ、MSN、电子邮箱、电话等，您的联系方式不会被公开)
*内容：
